The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

In 2024, drug makers lowered the cost of dozens of common medications to avoid penalties imposed by the American Rescue Plan, Katie Thomas of ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

A law signed in 2023 caps out-of-pocket costs for insulin, asthma inhalers, and epinephrine injectors beginning Jan. 1.

While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short ... to discontinue production of certain insulin presentations and more dated delivery technologies ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

This move is a milestone, he noted, as for the first time insulin is being produced as pens inside Egypt, after it was previously produced only in the form of injections. This achievement reflects ...

Eli Lilly announced FDA approval of Zepbound as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea. In addition, adults on Zepbound lost an average of 45 ...

Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...